These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 2272768)

  • 1. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
    Tamura K
    Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of idarubicin administered orally on a daily x 3 schedule.
    Stewart DJ; Verma S; Maroun JA; Robillard L; Perrault DJ; Young V; Gupta S; Fontaine B
    Invest New Drugs; 1990 Aug; 8(3):275-81. PubMed ID: 2272768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of oral idarubicin in advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Pronzato P; Repetto L; De Palma M; Canobbio L; Gulisano M; Fusco V; Rosso R; Ganzina F
    Cancer Invest; 1988; 6(4):409-11. PubMed ID: 2846128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly oral idarubicin in postmenopausal women with advanced breast cancer. A phase II study.
    Bastholt L; Dalmark M; Jakobsen A; Gadeberg CC; Sandberg E; Mouridsen HT
    Acta Oncol; 1990; 29(2):143-6. PubMed ID: 2334567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral idarubicin in measurable gastric cancer.
    Abad-Esteve A; Diaz-Rubio E; Jimeno JM; Rosell R; Villar A; Gonzalez-Larriba JL
    Am J Clin Oncol; 1989 Feb; 12(1):14-6. PubMed ID: 2912018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 4-demethoxydaunorubicin.
    Bonfante V; Ferrari L; Villani F; Bonadonna G
    Invest New Drugs; 1983; 1(2):161-8. PubMed ID: 6590530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
    Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
    Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies.
    Ganzina F; Pacciarini MA; Di Pietro N
    Invest New Drugs; 1986; 4(1):85-105. PubMed ID: 3516918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of orally administered idarubicin in patients with advanced breast cancer.
    Casper ES; Raymond V; Hakes TB; Currie VE; Kaufman RJ
    Cancer Treat Rep; 1987 Dec; 71(12):1289-90. PubMed ID: 3480045
    [No Abstract]   [Full Text] [Related]  

  • 11. Phase II study of oral idarubicin in patients with AIDS-associated Kaposi's sarcoma.
    Chachoua A; Green M; Laubenstein L; Wernz J; Muggia FM
    Cancer Treat Rep; 1987; 71(7-8):775-6. PubMed ID: 3475172
    [No Abstract]   [Full Text] [Related]  

  • 12. 4-Demethoxydaunorubicin (IMI-30) in refractory epithelial ovarian cancer: a pilot study.
    Bruzzone M; Chiara S; Falcone A; Graziani G; Conte PF; Rosso R
    Chemioterapia; 1987 Apr; 6(2):137-9. PubMed ID: 3474080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of oral 4-demethoxydaunorubicin in previously treated (except anthracyclines) metastatic breast cancer patients.
    Kolarić K; Mechl Z; Potrebica V; Sopkova B
    Oncology; 1987; 44(2):82-6. PubMed ID: 3472133
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.